Asensus Surgical, INC.: directors' dealings · United States · SEC (Form 4)

About Asensus Surgical, INC.

Asensus Surgical, Inc. is a medical technology company focused on robotic-assisted surgery and digitally enhanced minimally invasive procedures. The company traces its roots to TransEnterix and rebranded as Asensus Surgical in 2021 to better reflect its strategic shift toward data-driven surgical care and what it describes as Performance-Guided Surgery™. Its headquarters are in Research Triangle Park, North Carolina, United States. Before being acquired in August 2024, Asensus was listed on the NYSE American under the ticker ASXC. For investors, the key point is that the company is no longer independently traded after the completion of that transaction. At the center of Asensus’ business model was the Senhance Surgical System, a robotic-assisted platform designed to bring digital laparoscopy into routine operating-room use. The company also marketed the Intelligent Surgical Unit (ISU), an enabling system that added advanced visualization, augmented-intelligence features, and software-based support for surgeons. In parallel, Asensus was developing the LUNA Surgical System, intended as a next-generation robotic and instrument platform. Taken together, these offerings positioned the company in the fast-evolving segment of digital surgery, where the competitive edge depends not only on robotics hardware but also on software, analytics, workflow integration, and surgeon support tools. From a competitive standpoint, Asensus was a niche player in a market dominated by larger and much better capitalized medtech groups. That scale disadvantage was partly offset by a differentiated value proposition: lower-cost digital surgery concepts, real-time guidance features, and an emphasis on improving precision and consistency in minimally invasive surgery. The company’s systems were relevant across general surgery and selected specialty applications, with a particular focus on areas such as urology. Its positioning was therefore more innovative and technology-led than volume-led, which made it strategically interesting but financially more exposed than larger peers. Geographically, Asensus had an international footprint, with placements and commercial activity in North America, Europe, and Asia, including Japan and several European markets. Recent milestones included a 2024 FDA clearance expanding the Senhance system’s U.S. indication into urology, followed by the definitive acquisition by KARL STORZ, completed in August 2024. That deal ended ASXC’s life as a standalone public equity story on the NYSE American. For French, Belgian, and Swiss investors, Asensus is best understood today as a former listed U.S. surgical robotics company whose technology assets and product platform were absorbed into a larger global medtech group.